A practical reference on dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-17 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
The temperature at which the Leidenfrost effect appears is difficult to predict. Even if the volume of the drop of liquid stays the same, the Leidenfrost point may be quite different, with a complicated dependence on the properties of the surface, as well as any impurities in the liquid. Some research has been conducted into a theoretical model of the system, but it is quite complicated. The effect was also described by the Victorian steam boiler designer, William Fairbairn, in reference to its effect on massively reducing heat transfer from a hot iron surface to water, such as within a boiler. In a pair of lectures on boiler design, he cited the work of Pierre Hippolyte Boutigny (1798–1884) and Professor Bowman of King's College, London, in studying this. A drop of water that was vaporized almost immediately at 168 °C (334 °F) persisted for 152 seconds at 202 °C (396 °F). Lower temperatures in a boiler firebox might evaporate water more quickly as a result; compare Mpemba effect. An alternative approach was to increase the temperature beyond the Leidenfrost point. Fairbairn considered this, too, and may have been contemplating the flash steam boiler, but considered the technical aspects insurmountable for the time. The Leidenfrost point may also be taken to be the temperature for which the hovering droplet lasts longest. It has been demonstrated that it is possible to stabilize the Leidenfrost vapor layer of water by exploiting superhydrophobic surfaces.
===== Phase II ===== Bromazolam N-glucuronide, phenyl-hydroxy bromazolam glucuronide, α-hydroxy bromazolam glucuronide, and 4-hydroxy bromazolam glucuronide, were detected as phase II metabolites. Bromazolam N-glucuronidation was found to be catalysed by UGT1A4 and UGT2B10. The formation of α-hydroxy bromazolam glucuronide was catalysed by UGT2B4. And 4-hydroxy bromazolam glucuronidation was catalysed by UGT1A3, UGT1A6, UGT1A9, UGT2B7 and UGT2B15. The enzyme responsible for the catalysis for the phenyl-hydroxy bromazolam glucuronidation formation was not identified.
22 December A network model analysis suggests that temporary overshoots of climate change – increasing global temperature beyond Paris Agreement goals temporarily as often projected – can increase risks of climate tipping cascades "by up to 72%". In a paywalled article, scientists provide 3D imaging and model analysis to reveal main causes, mechanics, and potential mitigations of the problematic prevalent lithium-ion battery degradation over charge cycles. 26 December – Bio- and electrical engineers prove for the first time that human cerebral organoids transplanted into mice (see 17 Aug 21 and 12 Oct) functionally integrate with their visual cortex. 27 December – Scientists report that a species of Halteria, a single-celled protozoan, is the first known organism for which "a virus-only diet ... is enough to fuel the physiological growth and even population growth".
Sources: en.wikipedia.org
== Medical uses == Nandrolone esters are used clinically, although increasingly rarely, for people in catabolic states with major burns, cancer, and AIDS, and an ophthalmological formulation was available to support cornea healing. The positive effects of nandrolone esters include muscle growth, appetite stimulation and increased red blood cell production, and bone density. Clinical studies have shown them to be effective in treating anemia, osteoporosis, and breast cancer. Nandrolone sulfate has been used in an eye drop formulation as an ophthalmic medication.
== Uses == iRGD peptides have been shown to increase accumulation and penetration of anticancer drugs into tumors, but not into normal tissues – whether the drug is coupled to the peptide or given together with it. iRGD-mediated increased penetration and anti-cancer efficacy have been demonstrated with a variety of anti-cancer small molecules, nanoparticles and antibodies. Lisata Therapeutics Inc. is currently testing iRGD-based therapy called certepetide (aka LSTA1; CEND-1) in clinical studies in solid-tumor patients. The U.S. Food and Drug Administration (FDA) awarded certepetide orphan drug status in 2019, and fast-track designation in 2020.
=== Gene mutations === Several gene mutations have been identified in patients with camptocormia. These include the RYR1 gene in axial myopathy, the DMPK gene in myotonic dystrophy, and genes related to dysferlinopathy and Parkinson's disease. These genes could serve as targets for gene therapy to treat the condition in the years to come.
Sources: en.wikipedia.org
The racial makeup of Raleigh in 2023 was 52.5% non-Hispanic White, 28.1% Black or African American, 0.3% American Indian or Alaska Native, 4.5% Asian American, 0.1% from some other race, 6.9% two or more races, 11.6% Hispanic or Latin American of any race. According to the 2010 United States census, the racial composition of the city was: 57.5% White (53.3% non-Hispanic White), 29.3% Black or African American, 4.3% Asian American (1.2% Indian, 0.8% Chinese, 0.7% Vietnamese, 0.5% Korean, 0.4% Filipino, 0.1% Japanese), 2.6% two or more races, 1.4% some other race, 0.5% Native American, and <0.1% Native Hawaiian or other Pacific Islander In addition, 11.4% of city residents were Hispanic or Latino Americans, of any race (5.9% Mexican, 1.1% Puerto Rican, 0.9% Salvadoran, 0.6% Dominican, 0.6% Honduran, 0.3% Colombian, 0.3% Cuban, 0.2% Guatemalan, 0.2% Spanish, 0.2% Peruvian, 0.1% Venezuelan, 0.1% Ecuadorian, 0.1% Argentine, and 0.1% Panamanian). In 2000, the racial composition of the city was: 63.31% White, 27.80% Black or African American, 7.01% Hispanic or Latino American, 3.38% Asian American, 0.36% Native American, 0.04% Native Hawaiian or other Pacific Islander, 3.24% some other race, and 1.88% two or more races.
Caregiving is the ongoing physical, social, emotional support provided to people living with dementia, helping them carry out everyday activities. Since AD has no cure and it gradually renders people incapable of tending to their own needs, caregiving is essentially the treatment and must be carefully managed over the course of the disease. During the early and moderate stages, modifications to the living environment and lifestyle can increase safety and reduce caretaker burden. Examples of such modifications are the adherence to simplified routines, the placing of safety locks, the labeling of household items to cue the person with the disease or the use of modified daily life objects. Per the American Academy of Family Physicians, the use of physical restraints is discouraged. Use of the "VIPS" framework "(Valuing people, Individualised care, Personal perspectives, Social environment)" has been shown to reduce hours per day of restraint. If eating becomes problematic, food will need to be prepared in smaller pieces or even puréed. When swallowing difficulties arise, the use of feeding tubes may be required. In such cases, the medical efficacy and ethics of continuing feeding is an important consideration of the caregivers and family members. During the final stages of the disease, treatment is centred on relieving discomfort until death, often with the help of hospice. The wellbeing of caregivers themselves is an important aspect of AD caregiving.
== Plot == Jesse (Danny McBride), Judy (Edi Patterson) and Kelvin (Adam DeVine) participate in a rehearsal for the "Aimee-Leigh Birthday Celebration Give-A-Thon", hosted by Baby Billy (Walton Goggins). However, during their attempt to lift up, the Gemstones' jet packs malfunction and ruin part of the set. Billy scolds them and demands that they find Eli, who has gone missing for the past few days, as he is vital to the Give-A-Thon's success. Eli (John Goodman) has moved to Florida, living in a yacht where he drinks alcohol and has sex with strangers. Jesse, Judy and Kelvin arrive to get him to take part in the telethon, but Eli refuses, feeling he needs time to consider what he truly wants in life. Nevertheless, they force him to change his mind after repeating the word "pussy" to annoy him. BJ (Tim Baltz) now attends pole dancing classes, although Judy feels jealous of his female colleagues. Kelvin and Keefe (Tony Cavalero) have embraced their relationship and formed a new church program named "Prism", although Keefe wishes they would finally marry or kiss in public. The Gemstones have also launched "Prayer Pods" to the market, but sales are incredibly low. Billy surprises the family by bringing Lori Milsap (Megan Mullally), Aimee-Leigh's long-time musical partner. She and Eli bond, reminiscing over their experiences with Aimee-Leigh. During the telethon, Eli is amazed upon seeing Lori singing, and has a flirtatious encounter with her backstage.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。